“I believe US will go in the similar path as had on a heat not burning in other places. So two to three years, we should I could should be net net contributor to to the bottom line.”

In context

“etcetera, review FDA has gave authorizations for all variants of the I I wouldn't be my wouldn't be myself if I wouldn't comment that obviously, if something takes five years, it must be thorough because otherwise, I cannot fix explain, you know, the length of the process. But I do hope that, you know, FDA We'll move faster and, you know, already I could do my spending for a while. And by the way, if you have it also authorization, for for Zendesk. So the the margin story, I would repeat my self that, obviously, when we start adding support behind the behind the Lumen, I mean, at the initial period, will be a negative. Right? But in a scheme of the things, in the PNL size equal, like, of our business in the US, I don't think it should be something which is you know, that much worried. And I believe US will go in the similar path as had on a heat not burning in other places. So two to three years, we should I could should be net net contributor to to the bottom line. Bearing in mind, as always, reminding everyone that we don't really have the headwind of cannibalization. Right? So we don't really we're we're we're in a better starting position. And we know, we had a growing confidence in the ICOSI Lumen international, but we know where ICONZYLUM are brought us on international over the last three years. And it continues, you know, generating the growth user acquisition. So I believe it's really a great proposition for for adult smokers in the Emmanuel Babeau: Maybe just just to compliment on on the margin side, Bonnie. As you can, you know, judge from our guidance, we have significant ambition in terms of margin improvement in 2025 And what is driving that is the fact that we are flying on several engine here on margin improvement, and everything is c”